DMX-NB1 as a potential treatment of Opioid Use Disorder

DemeRx are planning to conduct a Phase II proof of concept study investigating the effects of their DMX-NB1 formulation for the treatment of Opioid Use Disorder.

DMX-NB1 is a formulation of NorIbogaine, an indole alkaloid with atypical opioid pharmacology that may offer unique opportunities to improve the treatment of opioid addiction.

Topic Addiction Opioid Use Disorder
Compound Ibogaine
Country United States of America
Visit trial
Status Planned
Results Published No
Chance of happening 79%
Phase Phase II
Design Open
Type Interventional
Generation Second
Sex All
Therapy No

Trial Details

NorIbogaine is an indole alkaloid with an atypical opioid pharmacology that may offer unique opportunities to improve the treatment of opioid addiction and to limit tolerance to opioid pain medications. We also plan to develop NorIbogaine as a subchronic adjunct therapy to support patients after Ibogaine detoxification who are in early recovery.

NCT Number

Sponsors & Collaborators

DemeRx
DemeRx is a subsidiary of atai that aims to develop ibogaine for Opioid Use Disorder.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.